CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial (Q46772484)

25 December 2017

title

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial (English)

1 reference

25 December 2017

0 references

1 reference

1 reference

György Bodoky

5

0 references

Bengt Glimelius

2

object named as

Bengt Glimelius

1 reference

25 December 2017

Viviane Hess

1

1 reference

25 December 2017

Philipp Grawe

3

1 reference

25 December 2017

Daniel Dietrich

4

1 reference

25 December 2017

Thomas Ruhstaller

6

1 reference

25 December 2017

Emilio Bajetta

7

1 reference

25 December 2017

Piercarlo Saletti

8

1 reference

25 December 2017

Arie Figer

9

1 reference

25 December 2017

Werner Scheithauer

10

1 reference

25 December 2017

Richard Herrmann

11

1 reference

25 December 2017

publication date

1 February 2008

1 reference

25 December 2017

Lancet Oncology Commission

published in

1 reference

25 December 2017

volume

9

1 reference

25 December 2017

issue

2

1 reference

25 December 2017

page(s)

132-138

1 reference

25 December 2017

Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

Specific Antigen in Serum of Patients with Colon Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

Reporting recommendations for tumor marker prognostic studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

On the relationship between response to treatment and survival time

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

Chemotherapy for advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970001-9

7 January 2021

10.1016/S1470-2045(08)70001-9

Identifiers

DOI

1 reference

25 December 2017

PubMed ID

18249033

1 reference

25 December 2017